- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04026841
The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.
July 31, 2019 updated by: Jianxing He, The First Affiliated Hospital of Guangzhou Medical University
The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density: A Prospective Interventional Two-stage Simon Design Phase II Study.
A single-center,prospective interventional study to explore the efficacy of PD-1 antibody Sintilimab on early-stage multiple primary lung cancer patients with ground-glass nodules in CT scan.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study is a single-center,prospective interventional clinical study, all subjects enrolled are multiple primary lung cancer patients with ground-glass density in CT scan.The samples plan for the study was 36 cases.The enrolled patients will receive intravenous infusion of Sintilimab 200mg every 3 weeks up to 4 cycles, and the efficacy will be evaluated after cycle 2 and 4 using RECIST criteria (version 1.1 ).
Study Type
Interventional
Enrollment (Anticipated)
36
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Wenhua Liang, PhD
- Phone Number: +86-02-83062808
- Email: liangwh1987@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Recruiting
- Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University
-
Contact:
- Wenhua Liang, PhD
- Phone Number: 0086-20-83062114
- Email: liangwh1987@163.com
-
Contact:
- Wenhua Liang, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Two or more ground-glass lesions (pure ground glass or partially solid) presented in the CT scan of lung that cannot be operated simultaneously
- There was at least one lung cancer lesion with a diameter of 1-3cm confirmed pathologically or by multidisciplinary team.
- Excluding lymph nodes and distant metastasis through imaging
- ECOG PS 0-1
- Vital organ functions meet the following requirements: 1)The absolute count of neutrophils ≥1.5×109/L 2)Platelet ≥90×109/L 3)Hemoglobin ≥9g/dL 4)Serum albumin ≥3g/dL 5)Thyroid stimulating hormone (TSH) ≤ULN (if abnormal, T3 and T4 levels should be examined at the same time; if T3 and T4 levels are normal, they can be included in the group) 6)Bilirubin ≤ULN 7)ALT and AST≤1.5 ULN 8)AKP≤ 2.5ULN or less 9)Serum creatinine ≤1.5 ULN or creatinine clearance ≥60mL/min
- Subjects volunteered to participate in this study and signed informed consent, with good compliance.
Exclusion Criteria:
- Non-calcified lesions with diameter more than 3mm are presented
- The presence of any active autoimmune diseases or a history of autoimmune diseases
- Those who have used other drugs in clinical study within 4 weeks before the first time of drug use
- Severe allergic reaction to monoclonal antibody
- Heart clinical symptoms or diseases are not well controlled
- Subjects with congenital or acquired immune deficiency (such as HIV infection) or active hepatitis
- According to the researcher's judgment, the subjects have other factors that may lead to the forced termination of this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PD-1 Antibody Sintilimab
Patients receive the treatment of PD-1 antibody Sintilimab
|
Patients in experimental group receive the treatment of PD-1 antibody Sintilimab
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR of target lesions.
Time Frame: 3 months
|
The objective response rate will be evaluated after 4 courses of treatment
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 3 months
|
The safty of PD-1 Antibody Sintilimab
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 30, 2019
Primary Completion (Anticipated)
February 1, 2020
Study Completion (Anticipated)
February 1, 2020
Study Registration Dates
First Submitted
July 17, 2019
First Submitted That Met QC Criteria
July 18, 2019
First Posted (Actual)
July 19, 2019
Study Record Updates
Last Update Posted (Actual)
August 2, 2019
Last Update Submitted That Met QC Criteria
July 31, 2019
Last Verified
July 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCTC1901
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Primary Lung Cancers
-
Fudan UniversityNot yet recruiting
-
Ruijin HospitalThe First Affiliated Hospital of Nanchang University; Second Affiliated Hospital... and other collaboratorsRecruitingMultiple Primary Lung CancersChina
-
Peking University People's HospitalGuangzhou Burning Rock Medical Examination Institute Co., Ltd.Not yet recruitingLung Cancer | Non Small Cell Lung Cancer | Multiple Primary Lung Cancers
-
Centre Leon BerardCompleted
-
RenJi HospitalRecruitingMultiple Synchronous Lung Cancers (MSLCs)China
-
Ruijin HospitalSun Yat-sen University; Shanghai General Hospital, Shanghai Jiao Tong University... and other collaboratorsRecruitingMultiple Primary Lung CancerChina
-
University Hospital, RouenCompletedBreast Cancer | Colorectal Cancer | Ovarian Cancer | Pediatric Cancers | Multiple Primary Malignant TumoursFrance
-
RenJi HospitalUnknownMultiple Primary NeoplasmChina
-
University of Colorado, DenverNational Cancer Institute (NCI); University of Kentucky; University of Louisville and other collaboratorsNot yet recruitingLung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung | Cancer, Lung | Cancer of the Lung | Pulmonary Neoplasm | Lung Cancers | Neoplasm, Pulmonary | Cancers, Lung | Cancer, Pulmonary | Cancers, Pulmonary | Pulmonary Cancers
-
Centre Leon BerardGlaxoSmithKlineRecruitingRecurrent Cancer | Second Cancer | Primary CancerFrance
Clinical Trials on PD-1 antibody Sintilimab
-
Cancer Hospital of Guangxi Medical UniversityRecruitingNasopharyngeal Carcinoma | SintilimabChina
-
Innovent Biologics (Suzhou) Co. Ltd.Active, not recruiting
-
Fudan UniversityRecruitingColorectal Cancer | Liver Metastases | Radiotherapy | ImmunotherapyChina
-
Sun Yat-sen UniversityRecruiting
-
Affiliated Cancer Hospital & Institute of Guangzhou...Not yet recruiting
-
Beijing Tongren HospitalRecruitingExtranodal NK/T-cell LymphomaChina
-
West China HospitalRecruitingImmunotherapy | SBRT | Stage IV HCCChina
-
Henan Cancer HospitalRecruitingGastric and Esophagogastric Junction AdenocarcinomaChina
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Beijing Tongren HospitalNot yet recruitingExtranodal NK/T-cell Lymphoma, Nasal Type